11th International Congress on Targeted Anticancer Therapies

February 28, 2013

Lugano/Amsterdam, 28 February 2013 -- A range of new and promising targeted drugs currently under development for improved cancer therapy will be presented during the 11th International Congress on Targeted Anticancer Therapies, Paris, 4-6 March 2013 (TAT 2013). The event, which is organised by NDDO Education Foundation, is an ESMO Partnership Meeting, co-sponsored by the U.S. National Cancer Institute.

Over 500 oncologists and scientists from all over the world will review and discuss cancer therapies of the future. Among them, many top academic experts involved in the early-phase clinical development of new targeted therapeutics and molecular cancer diagnostics, the cornerstones of personalised cancer therapy .

Personalised cancer medicine: targets and therapeutics

The development of new targeted cancer therapies is one of the main drivers for the further evolution of personalized cancer medicine. The concept of personalized medicine is based upon the notion that cancer development and progression are driven by genomic abnormalities and that these abnormalities are different not only between different types of cancer, but also between individual patients. Such findings have opened the door to the development of targeted cancer therapeutics, directed against tumour-specific molecular abnormalities.

At TAT 2013, over 50 plenary lectures and 70 posters will address dozens of emerging targeted agents and new drug targets under development for cancer therapy. In particular targets and experimental therapeutics in the early stages of clinical and the late stages of preclinical development will be addressed.

Program Highlights

-end-
Accepted abstracts can be obtained through the TAT Congress Secretariat[tat@congressbydesign.com] or the ESMO Press Office[media@esmo.org] prior to verification of the requesting journalist's credentials.

Abstracts are embargoed until March 1, midnight CET, and cannot be made public before that day. Journalists are kindly requested to observe embargoes.

Press registration

Bona fide journalists representing recognized news agencies, journals, magazine, newspapers, broadcast and online media may request a Complimentary Media Registration by sending an email to the congress management agency[tat@congressbydesign.com]. Journalists must present media credentials and their business card or a copy of their passport. Freelance journalists must, in addition, present a letter of assignment on the letterhead of a recognized news organization.

For further info:

ESMO Press Office
media@esmo.org

TAT Congress Secretariat
Email: tat@congressbydesign.com

European Society for Medical Oncology

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.